SIRPA and neoplasm: To date, ITIM bearing sialic acid-binding immunoglobulin-like lectins (Siglecs) expressed on myeloid cells have been discovered to bind to tumor cell ligands and inhibit immune responses in a manner similar to the CD47-SIRPα interaction.